Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Li, Lupeng ^a   Wang, Lixiang ^a   Song, Ping ^a   Geng, Xue ^a   Liang, Xiuming ^a   Zhou, Minran ^b   Wang, Yangyang ^a   Chen, Chunyan ^b   Jia, Jihui ^a   Zeng, Jiping ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Gastric cancer; RBP2; VEGF

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; HISTONE DEMETHYLASE; KI 67 ANTIGEN; RETINOBLASTOMA BINDING PROTEIN 2; VASCULOTROPIN; CELLULAR RETINOL BINDING PROTEIN; RBP2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ANALYSIS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURGERY; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR VOLUME; WESTERN BLOTTING; ADULT; AGED; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTIGENS, CD31; ANTIGENS, CD34; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MALE; MICE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETINOL-BINDING PROTEINS, CELLULAR; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898856724     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-81     Document Type: Article

References (44)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012, 13:790-801. 10.1016/S1470-2045(12)70211-5, 22658655.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010, 19:1893-1907. 10.1158/1055-9965.EPI-10-0437, 20647400.
3. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 2013, 14:e535-e547. 10.1016/S1470-2045(13)70436-4, 24176572.
4. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010, 29:405-434. 10.1007/s10555-010-9235-2, 2996866, 20737283.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
6. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009, 6:507-518. 10.1038/nrclinonc.2009.110, 19636328.
7. Gavalas NG, Liontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, Dimopoulos MA, Bamias A. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci 2013, 14:15885-15909. 10.3390/ijms140815885, 3759892, 23903048.
8. Katoh M. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med 2013, 32:763-767. 3812243, 23863927.
9. Ping SY, Shen KH, Yu DS. Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma. Mol Carcinog 2013, 52:568-579. 10.1002/mc.21892, 22392726.
10. Meng F, Onori P, Hargrove L, Han Y, Kennedy L, Graf A, Hodges K, Ueno Y, Francis T, Gaudio E, Francis HL. Regulation of the Histamine/VEGF Axis by miRNA-125b during Cholestatic Liver Injury in Mice. Am J Pathol 2014, 184:662-673. 10.1016/j.ajpath.2013.11.008, 24384130.
11. Ye P, Liu J, He F, Xu W, Yao K. Hypoxia-Induced Deregulation of miR-126 and Its Regulative Effect on VEGF and MMP-9 Expression. Int J Med Sci 2013, 11:17-23. 3880987, 24396282.
12. Chang CP, Bruneau BG. Epigenetics and cardiovascular development. Annu Rev Physiol 2012, 74:41-68. 10.1146/annurev-physiol-020911-153242, 22035349.
13. Ansari KI, Kasiri S, Mandal SS. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Oncogene 2013, 32:3359-3370. 10.1038/onc.2012.352, 3511651, 22926525.
14. Park D, Park H, Kim Y, Kim H, Jeoung D. HDAC3 acts as a negative regulator of angiogenesis. BMB Rep 2013, [Epub ahead of print].
15. Zeng J, Ge Z, Wang L, Li Q, Wang N, Björkholm M, Jia J, Xu D. The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 2010, 138:981-992. 10.1053/j.gastro.2009.10.004, 19850045.
16. Liang X, Zeng J, Wang L, Fang M, Wang Q, Zhao M, Xu X, Liu Z, Li W, Liu S, Yu H, Jia J, Chen C. Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS One 2013, 8:e69784. 10.1371/journal.pone.0069784, 3726779, 23922798.
17. Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang QKR, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG, Yan Q. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men. Proc Natl Acad Sci U S A 2011, 108:13379-13386. 10.1073/pnas.1110104108, 3158206, 21788502.
18. Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, Ooi A. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer. BMC Cancer 2010, 10:659. 3009982, 21118571.
19. Bridges E, Oon CE, Harris A. Notch regulation of tumor angiogenesis. Future Oncol 2011, 7:569-588. 10.2217/fon.11.20, 21463145.
20. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005, 438:937-945. 10.1038/nature04479, 16355211.
21. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013, 328:18-26. 10.1016/j.canlet.2012.08.018, 22922303.
22. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007, 13:4042-4045. 10.1158/1078-0432.CCR-06-2316, 17634527.
23. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178. 10.1016/j.cytogfr.2005.01.004, 15863032.
24. Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets 2010, 14:1047-1057. 10.1517/14728222.2010.511617, 3646329, 20854179.
25. Bzowska M, Me{ogonek}żyk-Kopeć R, Próchnicki T, Kulesza M, Klaus T, Bereta J. Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression. Acta Biochim Pol 2013, 60:263-275.
26. Soffietti R, Trevisan E, Bertero L, Bosa C, Ruda R. Anti-angiogenic approaches to malignant gliomas. Curr Cancer Drug Targets 2012, 12:279-288. 10.2174/156800912799277584, 22229250.
27. Shiva Shankar TV, Willems L. Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network. Vascul Pharmacol 2014, 60:57-66. 10.1016/j.vph.2014.01.003, 24445350.
28. Fujimoto S, Goda T, Mochizuki K. In vivo evidence of enhanced di-methylation of histone H3 K4 on upregulated genes in adipose tissue of diabetic db/db mice. Biochem Biophys Res Commun 2011, 404:223-227. 10.1016/j.bbrc.2010.11.097, 21110946.
29. Lee JE, Wang C, Xu S, Cho YW, Wang L, Feng X, Baldridge A, Sartorelli V, Zhuang L, Peng W, Ge K. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife 2013, 2:e01503. 10.7554/eLife.01503, 3869375, 24368734.
30. Wu L, Lee SY, Zhou B, Nguyen UT, Muir TW, Tan S, Dou Y. ASH2L regulates ubiquitylation signaling to MLL: trans-regulation of H3 K4 methylation in higher eukaryotes. Mol Cell 2013, 49:1108-1120. 10.1016/j.molcel.2013.01.033, 3615107, 23453805.
31. Ge W, Shi L, Zhou Y, Liu Y, Ma GE, Jiang Y, Xu Y, Zhang X, Feng H. nhibition of osteogenic differentiation of human adipose-derived stromal cells by retinoblastoma binding protein 2 repression of RUNX2-activated transcription. Stem Cells 2011, 29:1112-1125. 10.1002/stem.663, 21604327.
32. Sini D, Hansen KH, Christensen J, Agger K, Cloos PA, Helin K. Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2. Genes Dev 2008, 22:1345-1355. 10.1101/gad.470008, 2377189, 18483221.
33. Tu S, Teng YC, Yuan C, Wu YT, Chan MY, Cheng AN, Lin PH, Juan LJ, Tsai MD. The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif. Nat Struct Mol Biol 2008, 15:419-421. 10.1038/nsmb.1400, 18270511.
34. Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Gudas LJ, Mongan NP. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol 2013, 7:555-566. 10.1016/j.molonc.2013.01.003, 23384557.
35. Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Lelievre JD, Levy Y, Benkirane M. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol Cell 2012, 48:445-458. 10.1016/j.molcel.2012.08.022, 3595990, 23022380.
36. Ge Z, Li W, Wang N, Liu C, Zhu Q, Björkholm M, Gruber A, Xu D. Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J 2010, 24:579-586. 10.1096/fj.09-140087, 19762557.
37. van Oevelen C, Wang J, Asp P, Yan Q, Kaelin WG, Kluger Y, Dynlacht BD. A role for mammalian Sin3 in permanent gene silencing. Mol Cell 2008, 32:359-370. 10.1016/j.molcel.2008.10.015, 3100182, 18995834.
38. Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 2008, 22:1115-1140. 10.1101/gad.1652908, 2732404, 18451103.
39. Lopez-Bigas N, Kisiel TA, Dewaal DC, Holmes KB, Volkert TL, Gupta S, Love J, Murray HL, Young RA, Benevolenskaya EV. Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. Mol Cell 2008, 31:520-530. 10.1016/j.molcel.2008.08.004, 3003864, 18722178.
40. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594. 10.1016/j.cell.2010.04.020, 2882693, 20478252.
41. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80. 10.1016/j.cell.2010.02.027, 2851638, 20371346.
42. Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol 2013, 72:493-508. 10.1007/s00280-013-2220-z, 23820962.
43. Højfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 2013, 12:917-930. 10.1038/nrd4154, 24232376.
44. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005, 11:1386-1393. 10.1158/1078-0432.CCR-04-0487, 15746037.